Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
175 hedge funds and large institutions have $2.42B invested in Intercept Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 52 increasing their positions, 55 reducing their positions, and 23 closing their positions.
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
39% more capital invested
Capital invested by funds: $1.74B → $2.42B (+$679M)
7% more funds holding
Funds holding: 163 → 175 (+12)
1% more call options, than puts
Call options by funds: $191M | Put options by funds: $189M
5% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 55
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$26.6M |
| 2 |
Two Sigma Investments
New York
|
+$20.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$18.1M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$17.9M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
-$81.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$58.9M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$40M |
| 4 |
State Street
Boston,
Massachusetts
|
-$33.6M |
| 5 |
MAM
Melqart Asset Management
London,
United Kingdom
|
-$27.2M |
ICPT Hedge Fund Activity: Q3 2018 in Review
175 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2018, worth a combined $2.42B — up 39% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ICPT positions and 23 closed out — a net gain of 13 holders — while 52 added to existing stakes and 55 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $26.6M. The largest seller was Senvest Management, exiting entirely with an estimated $81.9M sold.
- 175 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2018, up from 163 in Q2 2018.
- Funds reported $2.42B of Intercept Pharmaceuticals, Inc. stock for Q3 2018, up 39% quarter-over-quarter.
- 36 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2018 and 23 closed out, a net change of +13 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2018 was First Trust Advisors, an estimated $26.6M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2018 was Senvest Management, an estimated $81.9M sold.
Based on aggregated 13F filings for Q3 2018.